Literature DB >> 8009572

Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals.

T Ishizaki1, D R Sohn, K Kobayashi, K Chiba, K H Lee, S G Shin, T Andersson, C G Regårdh, Y C Lou, Y Zhang.   

Abstract

Two independent studies showed that the 5-hydroxylation, but not the sulfoxidation, of omeprazole is more rapid in extensive metabolizers (EMs) than in poor metabolizers (PMs) of S-mephenytoin. In Caucasian, Chinese, and Korean PMs, the mean oral clearances were similar and not significantly different (85, 73, and 59 ml h-1 kg-1, respectively). However, the geometric mean clearance in Caucasian EMs (950 ml h-1 kg-1) was higher than in both Chinese EMs (426 ml h-1 kg-1, p < 0.05) and Korean EMs (446 ml h-1 kg-1, p < 0.01). The incidence of PMs of S-mephenytoin is higher in Chinese (14.6%) and Koreans (12.6%) than in Swedish Caucasians (3.3%). Therefore, the proportion of heterozygous compared to homozygous EMs is higher in Orientals than in Caucasians. This might explain the higher clearance of omeprazole in Caucasian EMs compared to the clearance of omeprazole in Chinese and Korean EMs of S-mephenytoin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8009572     DOI: 10.1097/00007691-199404000-00018

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  25 in total

1.  Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers.

Authors:  Yu-Cheng Sheng; Kun Wang; Ying-Chun He; Juan Yang; Qing-Shan Zheng
Journal:  Eur J Clin Pharmacol       Date:  2010-09-14       Impact factor: 2.953

2.  CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking.

Authors:  Margareta Ramsjö; Eleni Aklillu; Lilleba Bohman; Magnus Ingelman-Sundberg; Hyung-Keun Roh; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2010-05-25       Impact factor: 2.953

3.  Efficacy of S-pantoprazole 20 mg compared with pantoprazole 40 mg in the treatment of reflux esophagitis: a randomized, double-blind comparative trial.

Authors:  Yu Kyung Cho; Myung-Gyu Choi; Young-Tae Bak; Poong-Lyul Rhee; Sang Gyun Kim; Hoon-Yong Jung; Sang Young Seol
Journal:  Dig Dis Sci       Date:  2012-07-08       Impact factor: 3.199

4.  Different Clopidogrel Response Elicited by Lansoprazole or Esomeprazole in Patients Undergoing Neurointervention with Dual Antiplatelet Therapy.

Authors:  Kouhei Nii; Yusuke Morinaga; Takafumi Mitsutake; Ritsurou Inoue; Toshio Higashi
Journal:  Clin Drug Investig       Date:  2019-10       Impact factor: 2.859

Review 5.  Pharmacokinetic considerations in the eradication of Helicobacter pylori.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  2000-03       Impact factor: 6.447

6.  CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects.

Authors:  T Sakai; N Aoyama; T Kita; T Sakaeda; K Nishiguchi; Y Nishitora; T Hohda; D Sirasaka; T Tamura; Y Tanigawara; M Kasuga; K Okumura
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

7.  A comparative study on endoscopic ulcer healing of omeprazole versus rabeprazole with respect to CYP2C19 genotypic differences.

Authors:  Takashi Ando; Haruki Kato; Naohito Sugimoto; Yasuyuki Nagao; Nobuyuki Seto; Hitoshi Hongo; Hirokazu Kajikawa; Yutaka Isozaki; Makoto Shimozawa; Yuji Naito; Norimasa Yoshida; Takashi Ishizaki; Toshikazu Yoshikawa
Journal:  Dig Dis Sci       Date:  2005-09       Impact factor: 3.199

Review 8.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 9.  Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

Authors:  T Andersson
Journal:  Clin Pharmacokinet       Date:  1996-07       Impact factor: 6.447

Review 10.  Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.